{"id":"78a2cb333d06","type":"article","url":"https://hartvaat.nl/2026/01/01/diabetes-obesitas-en-de-metabole-drijfveren-van-perifeer-arterieel-vaatlijden/","title":"Diabetes, obesitas en de metabole drijfveren van perifeer arterieel vaatlijden","title_en":"Diabetes, Obesity, and the Metabolic Drivers of Peripheral Artery Disease: Lessons from Recent Forecasts.","category":"preventie","category_label":"Preventie","professions":["huisarts","internist"],"tags":["cardio-renaal-metabool","diabetes-en-hart","diabetes-type-1","figaro-dkd","metabole-acidose","microbioom","obesitas","perifeer-vaatlijden","select-trial","soul-trial","tirzepatide"],"journal":"Vascular health and risk management","doi":"10.2147/VHRM.S576743","source_url":"https://doi.org/10.2147/VHRM.S576743","authors":["Edward Jude","Hongyan Wang"],"significance":3,"published":"2026-01-01","source_date":"2026-01-01","image":"https://hartvaat.nl/global/img/446852548547.webp","kennis":["https://hartvaat.nl/kennis/cardiometabool/cardiometabool-spreekuur/","https://hartvaat.nl/kennis/preventie/statines-primaire-preventie/"],"congress":"","summary_en":"This review examines how diabetes and obesity contribute to peripheral artery disease through metabolic pathways, discussing new treatment perspectives and preventive strategies as PAD prevalence is projected to rise dramatically by 2050.","created":"2026-07-03T10:25:04Z","updated":"2026-07-03T13:24:31Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Een diepgaande review die uitlegt hoe diabetes en obesitas via metabole routes bijdragen aan het ontstaan van perifeer arterieel vaatlijden. De auteurs bespreken nieuwe behandelperspectieven en preventieve strategieën.","abstract_original":"Peripheral artery disease (PAD) is rapidly emerging as a global health priority, with projections indicating a dramatic rise in prevalence, mortality, and disability by 2050. Recent forecasts project an approximately 220% increase in PAD prevalence, with more than 360 million individuals affected globally by mid-century, largely driven by metabolic diseases-particularly diabetes and obesity. A recent population-based study forecasting the global burden of PAD provides compelling evidence that metabolic disease is the dominant driver of this alarming trend. This commentary highlights the critical interplay between metabolic risk factors and PAD progression, underscores the disproportionate burden expected in low- and middle-income countries, and calls for urgent, integrated strategies targeting metabolic health. Without decisive action to reduce diabetes, obesity, and related metabolic disorders, the looming global PAD crisis will further strain healthcare systems and deepen health inequities worldwide."}